Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
Asunción Mejías, Octavio RamiloDivision of Pediatric Infectious Diseases, The University of Texas Southwestern Medical Center and Children’s Medical Center, Dallas, Texas, USAAbstract: In respiratory syncytial virus (RSV) disease the balance between the in...
Guardado en:
Autores principales: | Asunción Mejías, Octavio Ramilo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/831d1b34705d4b61bd5e6e3576071836 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis
por: Brian M. Maas, et al.
Publicado: (2021) -
Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
por: Agata Antepowicz, et al.
Publicado: (2021) -
Unnecessary antibiotic treatment of children hospitalised with respiratory syncytial virus (RSV) bronchiolitis: risk factors and prescription patterns
por: Uri Obolski, et al.
Publicado: (2021) -
Factors Associated with Severe Lower Respiratory Tract Infection from Respiratory Syncytial Virus (RSV) in Thai Children
por: Atipotsawee Tungsupreechameth, et al.
Publicado: (2021) -
Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
por: Ben Artin, et al.
Publicado: (2021)